Protocol No
ASTELLAS-2215-CL-0203
Staff Member
Sameem Abedin
Phase
I/II
Summary
This project is being done to find out if the combination therapy of gilteritinib [ASP2215], venetoclax and azacitidine is safe and effective for treatment of recently diagnosed patients with FLT3 mutated AML who are not eligible for intensive chemotherapy.
Objective
A Phase 1/2, Study of Gilteritinib, Venetoclax and Azacitidine in Patients with AML
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
ClinicalTrials.gov